RARE DISEASE
Glossopharyngeal neuralgia
Glossopharyngeal neuralgia
Glossopharyngeal neuralgia
Drug discovery
0
drugs
With orphan designations
Overview
Glossopharyngeal neuralgia (GPN) is a rare neuropathic disorder characterized by sudden, unilateral, lancinating pain in the glossopharyngeal nerve distribution (throat, tongue base, ear, and tonsils), triggered by swallowing, coughing, or talking [1][5][16]. Etiology often involves vascular compression, tumors, or idiopathic factors [1][5]. Diagnosis relies on clinical evaluation, anesthetic response, and MRI to exclude structural causes [1][16]. First-line treatment includes anticonvulsants (e.g., carbamazepine, gabapentin), with surgical options (microvascular decompression, rhizotomy) for refractory cases [1][7][12].
Burden
Debilitating pain leads to reduced oral intake, weight loss, and impaired quality of life [2][5].
Misdiagnosis delays treatment (common confusion with trigeminal neuralgia), while vagally mediated syncope or bradycardia occurs in ~10% [7][16].
Cost burden stems from frequent ED visits, polypharmacy, and surgical interventions [6][12].
Therapies
Pharmacological: Carbamazepine (first-line), gabapentin, or pregabalin [1][18].
Interventional: Glossopharyngeal nerve blocks (local anesthetics ± steroids) or pulsed radiofrequency ablation [2][3][12].
Surgical: Microvascular decompression (80–90% efficacy in vascular compression cases) or nerve sectioning [1][12][16].
Categories: rare neurological diseases
Research Papers
391 drug discovery papers about Glossopharyngeal neuralgia, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
391 drug discovery papers about Glossopharyngeal neuralgia, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-07-01 | Glossopharyngeal Neuralgia secondary to basilar artery compression precipitated by hyperglycemic episodes- A Case Report
Abstract: Glossopharyngeal neuralgia (GN) is a rare cause of severe throat pain and odynophagia. It is rarer than trigeminal neuralgia (TN) and is often associated with vascular conflict. While there are well known non-compressive causes of such neuralgias but impact of hyperglycemia in precipitating or exacerbating its symptoms remains under-explored. Here, we present a case of a-67-year-old male who presented with acute, severe odynophagia and painful chewing. He was diagnosed with GN after excluding other possible causes. Investigations revealed poorly controlled diabetes mellitus (DM) and neuroimaging showed a vascular conflict with the basilar artery abutting the glossopharyngeal nerve. Interestingly, the neuralgic episodes were noted to get precipitated by hyperglycemia. Intensive glycemic control alleviated the neuralgic pain significantly. Hyperglycemia can worsen focal demyelination making it hyperexcitable. This case highlights the role of hyperglycemia in precipitating the GN in a patient with a rare vascular conflict. Although, we need large scale studies to prove such association but the rarity of GN is a speed breaker to such executions. Key words: Glossopharyngeal neuralgia, hyperglycemia, trigeminal neuralgia, vascular conflict.
2026-05-01 | C51-35 When Pain Stops the Heart: Glossopharyngeal Neuralgia-Asystole Syndrome Secondary to Tonsillar Carcinoma
Abstract Glossopharyngeal neuralgia-asystole syndrome (GN-AS) is a rare neurocardiogenic disorder in which paroxysms of sharp pain within the glossopharyngeal nerve territory trigger excessive vagal activation, resulting in bradycardia, hypotension, syncope, or even transient cardiac arrest. These events occur when afferent impulses from cranial nerve IX reflexively stimulate vagal efferent pathways in the medulla. Although GN-AS can occur idiopathically, it more often arises from secondary causes that irritate or compress the lower cranial nerves. Head-and-neck tumors, particularly tonsillar carcinoma, may provoke both neuralgic pain and cardioinhibitory syncope through local invasion of the glossopharyngeal and vagus nerves. A 55-year-old man with right-sided heart failure and recently diagnosed left tonsillar squamous cell carcinoma presented after his first radiation session with dizziness, nausea, and hypotension. While in the emergency department, his heart rate abruptly dropped to the 20s, followed by unresponsiveness and loss of pulse. A code blue was initiated; atropine and brief chest compressions restored circulation. ECG showed sinus rhythm with first-degree AV block and right bundle-branch block, unchanged from baseline. Laboratory results and troponin were unremarkable. During ICU monitoring, he experienced recurrent sharp left-sided jaw and throat pain followed within seconds by diaphoresis, bradycardia, and hypotension, each resolving after atropine. He subsequently had another brief cardiac arrest characterized by unresponsiveness and loss of pulses, with restoration of circulation following atropine administration. Neck CT demonstrated a soft-tissue mass at levels II-III consistent with known malignancy, and prior PET imaging had shown bulky level II-III cervical lymphadenopathy encasing the left carotid bifurcation and proximal internal carotid artery. The presentation was concerning for glossopharyngeal neuralgia-asystole syndrome. AV-nodal-blocking agents were discontinued, and carbamazepine plus corticosteroids were initiated for neuralgic pain and peritumoral edema. No further bradyarrhythmic episodes occurred thereafter. GN-AS is estimated to occur in 0.2-0.7 per 100,000 person-years. Reflex asystole results from intense vagal efferent discharge triggered by glossopharyngeal pain, often precipitated by swallowing, chewing, or talking. Differentiation from carotid-sinus hypersensitivity is essential, as the latter is painless and induced by neck movement or pressure. Recognition of the pain-preceding bradyarrhythmia pattern enables prompt neuralgic control and prevention of recurrent asystole. Glossopharyngeal neuralgia-asystole syndrome should be considered in patients with head-and-neck malignancy who develop pain-triggered bradycardia or syncope, as timely recognition and treatment can be lifesaving. This abstract is funded by: None
2026-04-09 | Case Report: Complexities in the Management of Glossopharyngeal Neuralgia: Lessons from a Refractory Case.
Glossopharyngeal neuralgia is a rare cranial neuropathy characterized by paroxysmal, severe pain localized to the sensory distribution of the glossopharyngeal nerve. Diagnostic overlap with trigeminal neuralgia can lead to misclassification and delays in effective management. We report a 76-year-old female with an 18-year history of right-sided tongue and facial pain initially misdiagnosed as trigeminal neuralgia. Despite undergoing radiotherapy, thermolesion, and microvascular decompression, she experienced recurrent episodes of severe pain. At presentation, she was receiving pregabalin, carbamazepine, and fentanyl transdermal patch with limited efficacy and notable adverse effects. Transition to oxycodone, in combination with optimized pregabalin, carbamazepine, and venlafaxine, led to substantial pain relief and improved functionality. Hyponatremia secondary to high-dose carbamazepine was identified and corrected by dose adjustment. This case underscores the diagnostic challenges of glossopharyngeal neuralgia and highlights the importance of individualized, multimodal treatment strategies. While surgical interventions may offer partial benefit, adjunctive pharmacotherapy, including opioid therapy in refractory cases, can be essential for achieving adequate pain control.
2026-03-03 | Successful Management of Eagle Syndrome in a Patient With Repeated Office-Based, Ultrasound-Guided Nerve Blocks: A Case Report.
Eagle syndrome is a form of glossopharyngeal neuralgia, usually seen in older adults and characterized by pain in the throat, side of the face, and neck due to an elongated styloid process or calcified stylohyoid ligament. This condition can be managed with multimodal analgesia by multidisciplinary teams and may require surgical intervention for definitive relief. A 65-year-old female presented to the pain management clinic with chronic recurrent left-sided submandibular and neck pain. The pain was moderate in intensity (numeric rating scale (NRS) 5/10), episodic, sharp, burning, and electric shock-like in nature, and was associated with coughing and swallowing. She obtained only temporary and partial relief from medications. Her symptoms were successfully managed with repeated office-based ultrasound-guided glossopharyngeal nerve blocks using 3 ml of 0.25% ropivacaine and 4 mg dexamethasone. Significant improvement was maintained for approximately three months after the procedure.
2026-01-22 | Glossopharyngeal neuralgia after SARS-CoV-2 infection: A case report.
Glossopharyngeal neuralgia (GN) is a rare neuropathic disorder characterized by sudden, unilateral, electric shock-like pain in the areas innervated by the glossopharyngeal nerve. Its diagnosis is frequently delayed because of its clinical overlap with odontogenic and otorhinolaryngological conditions. In the context of the COVID-19 pandemic, different cranial neuropathies have been reported, suggesting possible post-infectious mechanisms. We describe the case of a 54-year-old male dentist, without relevant medical history, who developed recurrent episodes of intense pain in the right pharynx and base of tongue after confirmed SARS-CoV-2 infection. Symptoms were triggered by swallowing, coughing, and salivary stimulation, reaching maximum intensity on the visual analogue scale (EVA 10/10). Brain and neck magnetic resonance imaging revealed no structural abnormalities. Treatment with carbamazepine (600 mg/day) partially reduced frequency and severity of attacks, while pregabalin (300 mg/day) showed no benefit. This case highlights the need to consider SARS-CoV-2 infection as a potential trigger of GN, underscores the importance of recent infectious history in the differential diagnosis, and emphasizes the relevance of early pharmacological management in clinical improvement.
proteins
2022-12-14 | Refractory glossopharyngeal neuralgia successfully treated with onabotulinumtoxinA: A case report.
Glossopharyngeal neuralgia is a rare but severe and disabling pain condition often caused by vascular compression of the glossopharyngeal nerve. Treatment is similar to that of trigeminal neuralgia, but some patients may be refractory to both medical and surgical approaches. Here we present a case of refractory glossopharyngeal neuralgia that responded well to onabotulinumtoxinA (BTX-A). We report a case of a 65-year-old man with well-controlled human immunodeficiency virus disease with glossopharyngeal neuralgia symptoms since 2015. He had partial response to medications but was limited by side-effects. He underwent microvascular decompression twice with initial relief both times, but experienced recurrence of attacks 1-3 years after each surgery. He was treated with BTX-A using the chronic migraine PREEMPT protocol (i.e., 31-39 injection sites in head and neck muscles), which led to significant relief of his glossopharyngeal neuralgia pain. This is the first case to our knowledge of glossopharyngeal neuralgia treated with BTX-A. BTX-A can be an effective treatment for glossopharyngeal neuralgia, even when injections are not administered directly over the sensory distribution of the glossopharyngeal nerve.
cell therapies
2023-02-07 | Epithelial plasticity enhances regeneration of committed taste receptor cells following nerve injury.
Taste receptor cells are taste bud epithelial cells that are dependent upon the innervating nerve for continuous renewal and are maintained by resident tissue stem/progenitor cells. Transection of the innervating nerve causes degeneration of taste buds and taste receptor cells. However, a subset of the taste receptor cells is maintained without nerve contact after glossopharyngeal nerve transection in the circumvallate papilla in adult mice. Here, we revealed that injury caused by glossopharyngeal nerve transection triggers the remaining differentiated K8-positive taste receptor cells to dedifferentiate and acquire transient progenitor cell-like states during regeneration. Dedifferentiated taste receptor cells proliferate, express progenitor cell markers (K14, Sox2, PCNA) and form organoids in vitro. These data indicate that differentiated taste receptor cells can enter the cell cycle, acquire stemness, and participate in taste bud regeneration. We propose that dedifferentiated taste receptor cells in combination with stem/progenitor cells enhance the regeneration of taste buds following nerve injury.
small molecules
2026-07-01 | Glossopharyngeal Neuralgia secondary to basilar artery compression precipitated by hyperglycemic episodes- A Case Report
Abstract: Glossopharyngeal neuralgia (GN) is a rare cause of severe throat pain and odynophagia. It is rarer than trigeminal neuralgia (TN) and is often associated with vascular conflict. While there are well known non-compressive causes of such neuralgias but impact of hyperglycemia in precipitating or exacerbating its symptoms remains under-explored. Here, we present a case of a-67-year-old male who presented with acute, severe odynophagia and painful chewing. He was diagnosed with GN after excluding other possible causes. Investigations revealed poorly controlled diabetes mellitus (DM) and neuroimaging showed a vascular conflict with the basilar artery abutting the glossopharyngeal nerve. Interestingly, the neuralgic episodes were noted to get precipitated by hyperglycemia. Intensive glycemic control alleviated the neuralgic pain significantly. Hyperglycemia can worsen focal demyelination making it hyperexcitable. This case highlights the role of hyperglycemia in precipitating the GN in a patient with a rare vascular conflict. Although, we need large scale studies to prove such association but the rarity of GN is a speed breaker to such executions. Key words: Glossopharyngeal neuralgia, hyperglycemia, trigeminal neuralgia, vascular conflict.
2026-05-01 | C51-35 When Pain Stops the Heart: Glossopharyngeal Neuralgia-Asystole Syndrome Secondary to Tonsillar Carcinoma
Abstract Glossopharyngeal neuralgia-asystole syndrome (GN-AS) is a rare neurocardiogenic disorder in which paroxysms of sharp pain within the glossopharyngeal nerve territory trigger excessive vagal activation, resulting in bradycardia, hypotension, syncope, or even transient cardiac arrest. These events occur when afferent impulses from cranial nerve IX reflexively stimulate vagal efferent pathways in the medulla. Although GN-AS can occur idiopathically, it more often arises from secondary causes that irritate or compress the lower cranial nerves. Head-and-neck tumors, particularly tonsillar carcinoma, may provoke both neuralgic pain and cardioinhibitory syncope through local invasion of the glossopharyngeal and vagus nerves. A 55-year-old man with right-sided heart failure and recently diagnosed left tonsillar squamous cell carcinoma presented after his first radiation session with dizziness, nausea, and hypotension. While in the emergency department, his heart rate abruptly dropped to the 20s, followed by unresponsiveness and loss of pulse. A code blue was initiated; atropine and brief chest compressions restored circulation. ECG showed sinus rhythm with first-degree AV block and right bundle-branch block, unchanged from baseline. Laboratory results and troponin were unremarkable. During ICU monitoring, he experienced recurrent sharp left-sided jaw and throat pain followed within seconds by diaphoresis, bradycardia, and hypotension, each resolving after atropine. He subsequently had another brief cardiac arrest characterized by unresponsiveness and loss of pulses, with restoration of circulation following atropine administration. Neck CT demonstrated a soft-tissue mass at levels II-III consistent with known malignancy, and prior PET imaging had shown bulky level II-III cervical lymphadenopathy encasing the left carotid bifurcation and proximal internal carotid artery. The presentation was concerning for glossopharyngeal neuralgia-asystole syndrome. AV-nodal-blocking agents were discontinued, and carbamazepine plus corticosteroids were initiated for neuralgic pain and peritumoral edema. No further bradyarrhythmic episodes occurred thereafter. GN-AS is estimated to occur in 0.2-0.7 per 100,000 person-years. Reflex asystole results from intense vagal efferent discharge triggered by glossopharyngeal pain, often precipitated by swallowing, chewing, or talking. Differentiation from carotid-sinus hypersensitivity is essential, as the latter is painless and induced by neck movement or pressure. Recognition of the pain-preceding bradyarrhythmia pattern enables prompt neuralgic control and prevention of recurrent asystole. Glossopharyngeal neuralgia-asystole syndrome should be considered in patients with head-and-neck malignancy who develop pain-triggered bradycardia or syncope, as timely recognition and treatment can be lifesaving. This abstract is funded by: None
2026-04-09 | Case Report: Complexities in the Management of Glossopharyngeal Neuralgia: Lessons from a Refractory Case.
Glossopharyngeal neuralgia is a rare cranial neuropathy characterized by paroxysmal, severe pain localized to the sensory distribution of the glossopharyngeal nerve. Diagnostic overlap with trigeminal neuralgia can lead to misclassification and delays in effective management. We report a 76-year-old female with an 18-year history of right-sided tongue and facial pain initially misdiagnosed as trigeminal neuralgia. Despite undergoing radiotherapy, thermolesion, and microvascular decompression, she experienced recurrent episodes of severe pain. At presentation, she was receiving pregabalin, carbamazepine, and fentanyl transdermal patch with limited efficacy and notable adverse effects. Transition to oxycodone, in combination with optimized pregabalin, carbamazepine, and venlafaxine, led to substantial pain relief and improved functionality. Hyponatremia secondary to high-dose carbamazepine was identified and corrected by dose adjustment. This case underscores the diagnostic challenges of glossopharyngeal neuralgia and highlights the importance of individualized, multimodal treatment strategies. While surgical interventions may offer partial benefit, adjunctive pharmacotherapy, including opioid therapy in refractory cases, can be essential for achieving adequate pain control.
2026-03-03 | Successful Management of Eagle Syndrome in a Patient With Repeated Office-Based, Ultrasound-Guided Nerve Blocks: A Case Report.
Eagle syndrome is a form of glossopharyngeal neuralgia, usually seen in older adults and characterized by pain in the throat, side of the face, and neck due to an elongated styloid process or calcified stylohyoid ligament. This condition can be managed with multimodal analgesia by multidisciplinary teams and may require surgical intervention for definitive relief. A 65-year-old female presented to the pain management clinic with chronic recurrent left-sided submandibular and neck pain. The pain was moderate in intensity (numeric rating scale (NRS) 5/10), episodic, sharp, burning, and electric shock-like in nature, and was associated with coughing and swallowing. She obtained only temporary and partial relief from medications. Her symptoms were successfully managed with repeated office-based ultrasound-guided glossopharyngeal nerve blocks using 3 ml of 0.25% ropivacaine and 4 mg dexamethasone. Significant improvement was maintained for approximately three months after the procedure.
2026-01-22 | Glossopharyngeal neuralgia after SARS-CoV-2 infection: A case report.
Glossopharyngeal neuralgia (GN) is a rare neuropathic disorder characterized by sudden, unilateral, electric shock-like pain in the areas innervated by the glossopharyngeal nerve. Its diagnosis is frequently delayed because of its clinical overlap with odontogenic and otorhinolaryngological conditions. In the context of the COVID-19 pandemic, different cranial neuropathies have been reported, suggesting possible post-infectious mechanisms. We describe the case of a 54-year-old male dentist, without relevant medical history, who developed recurrent episodes of intense pain in the right pharynx and base of tongue after confirmed SARS-CoV-2 infection. Symptoms were triggered by swallowing, coughing, and salivary stimulation, reaching maximum intensity on the visual analogue scale (EVA 10/10). Brain and neck magnetic resonance imaging revealed no structural abnormalities. Treatment with carbamazepine (600 mg/day) partially reduced frequency and severity of attacks, while pregabalin (300 mg/day) showed no benefit. This case highlights the need to consider SARS-CoV-2 infection as a potential trigger of GN, underscores the importance of recent infectious history in the differential diagnosis, and emphasizes the relevance of early pharmacological management in clinical improvement.
proteins
2022-12-14 | Refractory glossopharyngeal neuralgia successfully treated with onabotulinumtoxinA: A case report.
Glossopharyngeal neuralgia is a rare but severe and disabling pain condition often caused by vascular compression of the glossopharyngeal nerve. Treatment is similar to that of trigeminal neuralgia, but some patients may be refractory to both medical and surgical approaches. Here we present a case of refractory glossopharyngeal neuralgia that responded well to onabotulinumtoxinA (BTX-A). We report a case of a 65-year-old man with well-controlled human immunodeficiency virus disease with glossopharyngeal neuralgia symptoms since 2015. He had partial response to medications but was limited by side-effects. He underwent microvascular decompression twice with initial relief both times, but experienced recurrence of attacks 1-3 years after each surgery. He was treated with BTX-A using the chronic migraine PREEMPT protocol (i.e., 31-39 injection sites in head and neck muscles), which led to significant relief of his glossopharyngeal neuralgia pain. This is the first case to our knowledge of glossopharyngeal neuralgia treated with BTX-A. BTX-A can be an effective treatment for glossopharyngeal neuralgia, even when injections are not administered directly over the sensory distribution of the glossopharyngeal nerve.
cell therapies
2023-02-07 | Epithelial plasticity enhances regeneration of committed taste receptor cells following nerve injury.
Taste receptor cells are taste bud epithelial cells that are dependent upon the innervating nerve for continuous renewal and are maintained by resident tissue stem/progenitor cells. Transection of the innervating nerve causes degeneration of taste buds and taste receptor cells. However, a subset of the taste receptor cells is maintained without nerve contact after glossopharyngeal nerve transection in the circumvallate papilla in adult mice. Here, we revealed that injury caused by glossopharyngeal nerve transection triggers the remaining differentiated K8-positive taste receptor cells to dedifferentiate and acquire transient progenitor cell-like states during regeneration. Dedifferentiated taste receptor cells proliferate, express progenitor cell markers (K14, Sox2, PCNA) and form organoids in vitro. These data indicate that differentiated taste receptor cells can enter the cell cycle, acquire stemness, and participate in taste bud regeneration. We propose that dedifferentiated taste receptor cells in combination with stem/progenitor cells enhance the regeneration of taste buds following nerve injury.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.